GSK seeks to expand Nucala's label

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Nucala mepolizumab met the co-primary endpoints of a Phase III study to treat eosinophilic granulomatosis with polyangiitis (EGPA), or inflammation of the walls of small blood vessels. The company plans to submit regulatory applications for the indication next year.

The company markets the IgG mAb against IL-5 in the EU and U.S. to treat severe refractory eosinophilic asthma...